Define the oncogenic role of Plk1 during hepatocellular carcinoma development using a genetically modified mouse model
使用转基因小鼠模型定义 Plk1 在肝细胞癌发展过程中的致癌作用
基本信息
- 批准号:10729603
- 负责人:
- 金额:$ 15.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelBiological AssayBiological ModelsCancer EtiologyCarcinomaCell Cycle CheckpointCell ProliferationCessation of lifeCharacteristicsClinicalClinical DataData SetDevelopmentDiethylnitrosamineDiseaseGenesGeneticHepatocarcinogenesisHepatocyteHeterogeneityHumanIncidenceInvadedInvestigationKnowledgeLiverLiver diseasesLocationLymphomaMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of liverMeta-AnalysisMitoticMolecularMonitorMusMutationNeoplasmsOncogenicOutcomePLK1 genePathogenesisPatientsPlayPre-Clinical ModelPrimary carcinoma of the liver cellsPropertyProto-OncogenesResearchRoleTestingTherapeuticTransgenesTransgenic MiceTransgenic ModelTransgenic OrganismsTumor Biologycancer therapycancer typedruggable targetin vivoinsightmortalitymouse modelnovelsarcomasenescencetargeted treatmenttooltumortumorigenesis
项目摘要
Hepatocellular carcinoma (HCC) represents one of the most common malignancies in humans
and the leading cause of cancer-related death worldwide, with a steadily increasing incidence and
. A major hallmark of HCC is its high heterogeneity in clinical presentation and
underlying tumor biology. Therefore, there is an urgent need to understand the molecular
pathogenesis of the disease, and to explore novel targets and strategies for the management of
HCC. Mammalian polo-like kinase 1 (Plk1) is a key mitotic regulator that has been implicated in
the initiation and progression of various types of cancer, including liver cancers, and has
subsequently been highlighted as a promising target for anticancer therapy. We generated Plk1
transgenic mice with globally elevated expression of Plk1, which showed marked increases in
tumor incidence, when compared to wild-type littermates, with HCC being the second most
predominant neoplasm observed. Furthermore, our meta-analysis of the publicly available clinical
datasets demonstrates that Plk1 is frequently upregulated in HCC and is significantly correlated
with poorer patient survival. The strong clinical evidence and the striking abnormality present in
the livers of Plk1 transgenic mice strongly suggests a role of Plk1 in the pathogenesis of HCC
development, and thereby prompted us to investigate whether elevated levels of Plk1 drives liver
carcinogenesis. In this study, we propose to define the oncogenic role of Plk1 during HCC
development using a genetically modified mouse model. The central hypothesis is that Plk1
functions as a prominent proto-oncogene in HCC. We propose the following specific aims: 1)
Generate liver-specific Plk1 transgenic mice; and 2) Determine hepatocarcinogenesis in liver-
specific Plk1 transgenic mice. This study will allow us to establish the first liver-specific Plk1
transgenic murine model, with which we will use to unambiguously dissect the oncogenic function
of Plk1 during hepatocarcinognesis and determine whether Plk1 is a driver gene of this invariably
fatal disease. The knowledge gained from this study will not only enhance our understanding of
the pathogenesis of HCC also provide important insights into the management of HCC, and our
liver-specific Plk1 transgenic model will serve as the ideal pre-clinical model to test mechanism-
based therapeutic approaches that target PLK1 in advanced and metastatic HCC. Furthermore,
this animal model provides an important research tool for exploring interactions of some of the
genetic alterations observed in HCC patients. Plk1’s function may go beyond
hepatocarcinogenesis; our liver-specific Plk1 transgenic mouse model will also shed light on its
possible role in other liver diseases.
mortality rate
肝细胞癌是人类最常见的恶性肿瘤之一
是全球癌症相关死亡的主要原因,发病率稳步上升,
. HCC的一个主要标志是其临床表现的高度异质性,
潜在的肿瘤生物学。因此,迫切需要了解分子
疾病的发病机制,并探索新的目标和战略的管理,
HCC。哺乳动物polo样激酶1(Plk 1)是一种关键的有丝分裂调节因子,
包括肝癌在内的各种类型癌症的发生和发展,
随后被强调为抗癌治疗的有希望的靶点。我们生成了Plk 1
Plk 1表达全面升高的转基因小鼠,
肿瘤发病率,与野生型同窝仔相比,HCC是第二大
观察到主要肿瘤。此外,我们对公开的临床研究的荟萃分析
数据集表明Plk 1在HCC中频繁上调,并且与HCC的发生和发展显著相关。
患者生存率更低。强有力的临床证据和显著的异常存在于
Plk 1转基因小鼠的肝脏强烈提示Plk 1在HCC发病机制中的作用
发展,从而促使我们研究Plk 1水平升高是否会驱动肝脏
致癌作用在这项研究中,我们建议确定Plk 1在HCC中的致癌作用,
使用转基因小鼠模型进行开发。中心假设是Plk 1
在HCC中作为一个突出的原癌基因发挥作用。我们提出以下具体目标:1)
产生肝脏特异性Plk 1转基因小鼠;和2)确定肝脏中的肝癌发生-
Plk 1转基因小鼠。这项研究将使我们能够建立第一个肝脏特异性Plk 1
转基因小鼠模型,我们将使用它来明确剖析致癌功能
Plk 1在肝癌发生中的作用,并确定Plk 1是否是这一恒定的驱动基因。
致命的疾病从这项研究中获得的知识不仅会提高我们对
肝癌的发病机制也为肝癌的治疗提供了重要的见解,我们的研究表明,
肝脏特异性Plk 1转基因模型将作为理想的临床前模型来测试机制-
在晚期和转移性HCC中靶向PLK 1的治疗方法。此外,委员会认为,
该动物模型为探索某些细胞因子之间的相互作用提供了重要的研究工具。
在HCC患者中观察到的遗传改变。Plk 1的功能可能超越
我们的肝脏特异性Plk 1转基因小鼠模型也将揭示其在肝癌发生中的作用。
在其他肝脏疾病中的作用。
死亡率
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHENG FU其他文献
ZHENG FU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHENG FU', 18)}}的其他基金
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 15.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




